Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: A pilot study

Endocrinology and Metabolism

Volumn 31, Issue 1, 2016, Pages 161-167

  Bae, Jaehyun ^a   Lee, Min Jung ^b   Choe, Eun Yeong ^c   Jung, Chang Hee ^b   Wang, Hye Jin ^a   Kim, Myoung Soo ^d   Kim, Yu Seun ^d   Park, Joong Yeol ^b   Kang, Eun Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Cyclosporine; Diabetes mellitus; Dipeptidyl peptidase IV inhibitors; Kidney transplantation; Linagliptin; Sitagliptin phosphate; Vildagliptin

Indexed keywords

EID: 84962705569     PISSN: 2093596X     EISSN: 20935978     Source Type: Journal    
DOI: 10.3803/EnM.2016.31.1.161     Document Type: Article

References (28)

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331:365-76.
2. Schiel R, Heinrich S, Steiner T, Ott U, Stein G. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus. Nephrol Dial Transplant 2005;20:611-7.
3. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84.
4. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009;76 Suppl 5:S28-38.
5. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34 Suppl 2:S276-8.
6. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58.
7. Fuchs H, Runge F, Held HD. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci 2012;45:533-8.
8. Cohen DJ, Loertscher R, Rubin MF, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984;101:667-82.
9. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374-84.
10. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998;31:309-16.
11. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007;3:81-92.
12. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995;28:547-59.
13. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
15. Valderhaug TG, Hjelmesæth J, Hartmann A, Roislien J, Bergrem HA, Leivestad T, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011;54:1341-9.
16. Thomas MC, Mathew TH, Russ GR. Glycaemic control and graft loss following renal transplantation. Nephrol Dial Transplant 2001;16:1978-82.
17. Wiesbauer F, Heinze G, Regele H, Horl WH, Schernthaner GH, Schwarz C, et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation 2010;89:612-9.
18. Hecking M, Kainz A, Werzowa J, Haidinger M, Doller D, Tura A, et al. Glucose metabolism after renal transplantation. Diabetes Care 2013;36:2763-71.
19. Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, et al. Vildagliptin preserves the mass and function of pancreatic ß cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 2013;15:153-63.
20. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves ß-cell mass in non-obese diabetic mice. J Endocrinol 2012;214:381-7.
21. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf 2011;6:304-9.
22. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83.
23. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88.
24. He YL, Sabo R, Sunkara G, Bizot MN, Riviere GJ, Leon S, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007;47:998-1004.
25. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78.
26. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001;60:156-66.
27. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007;47:165-74.
28. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25.